Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, 615 N. Wolfe Street, Baltimore, MD, 21205, USA.
Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, 615 N. Wolfe Street, Baltimore, MD, 21205, USA; Johns Hopkins School of Medicine, Department of Infectious Disease, Baltimore, MD, USA.
Drug Alcohol Depend. 2021 Apr 1;221:108584. doi: 10.1016/j.drugalcdep.2021.108584. Epub 2021 Feb 13.
There is limited data on the health and social consequences of the COVID-19 pandemic among people who inject drugs (PWID).
We conducted a rapid telephone survey from April-June 2020 among participants of the community-based AIDS Linked to the IntraVenous Experience (ALIVE) cohort study in Baltimore, Maryland. This interviewer-administered survey collected information on COVID-19 knowledge, symptoms, testing, diagnosis, and prevention behaviors, recent substance use, housing conditions, interruptions to healthcare, access to harm reduction and drug treatment, mental health, and social support.
Of 443 current and former PWID who participated in the survey, 36 % were female, 85 % were Black, 33 % were living with HIV and 50 % reported any substance use in the prior six months. COVID-19 awareness was high, but knowledge of symptoms and routes of transmission were lower. PWID reporting recent substance use were less likely to always socially distance (63 % vs. 74 % among those without recent use, p = 0.02), and Black PWID were more likely than non-Black to socially distance (73 % vs. 48 %, p < 0.0001) and use when alone (68 % vs.35 %, p < 0.01). Only 6% reported difficulty accessing healthcare, yet only 48 % of those on opioid-agonist treatment had a four-week supply available. While 34 % reported increased depressive symptoms, participants reported high levels of social support.
This rapid assessment highlighted that PWID currently using drugs may be less able to practice social distancing and increased SARS-CoV-2 transmission may occur. Ongoing monitoring of substance use and mental health, as well as overdose prevention is necessary as the pandemic and public health responses continue.
目前关于 COVID-19 大流行对注射毒品者(PWID)的健康和社会影响的数据有限。
我们在 2020 年 4 月至 6 月期间对马里兰州巴尔的摩市基于社区的艾滋病与静脉内经验(ALIVE)队列研究的参与者进行了快速电话调查。这项由访谈者管理的调查收集了关于 COVID-19 知识、症状、检测、诊断和预防行为、最近的物质使用、住房条件、医疗保健中断、获得减少伤害和药物治疗、心理健康和社会支持的信息。
在参与调查的 443 名现用和前用注射毒品者中,36%为女性,85%为黑人,33%感染了 HIV,50%报告在过去六个月内有任何物质使用。COVID-19 的意识很高,但对症状和传播途径的了解较低。报告最近物质使用的 PWID 不太可能始终保持社交距离(63%与最近没有物质使用的人相比,p=0.02),而黑人 PWID 比非黑人更有可能保持社交距离(73%与 48%,p<0.0001)和独处时使用(68%与 35%,p<0.01)。只有 6%报告难以获得医疗保健,但只有 48%接受阿片类激动剂治疗的人有四周的供应。尽管 34%报告抑郁症状增加,但参与者报告了高水平的社会支持。
这项快速评估强调,目前使用毒品的 PWID 可能较难保持社交距离,可能会增加 SARS-CoV-2 的传播。随着大流行和公共卫生应对措施的继续,有必要继续监测物质使用和心理健康以及预防过量用药。